Skip to content
Screener

Dyne Therapeutics, Inc. DYN Net Change in Cash

Net Change in Cash at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$336.83M+60.9%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$198.88M-999%
Arrowhead Research logo
Arrowhead ResearchARWR
-$14.12M-111%
Wave Life Sciences logo
Wave Life SciencesWVE
-$176.58M-411%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$236.56M+81.4%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$27.94M-438%

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$4.83B+193%
Enterprise value$4.25B+231%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 7:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-215702
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Repayments under vendor financing arrangement(579)
Proceeds from issuance of common stock in at-the-market offering, net of issuance costs140,653
Net cash provided by financing activities7,064141,241
Net increase (decrease) in cash, cash equivalents and restricted cash(140,250)36,806
Cash, cash equivalents and restricted cash, beginning of period895,740437,391
Cash, cash equivalents and restricted cash, end of period$755,490$474,197
Supplemental disclosures of cash flow information:
Purchase of property and equipment in accounts payable$77$29

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dyne Therapeutics, Inc.'s net change in cash?
Dyne Therapeutics, Inc. (DYN) reported net change in cash of -$140.25M in Q1 2026.
How has Dyne Therapeutics, Inc.'s net change in cash changed year-over-year?
Dyne Therapeutics, Inc.'s net change in cash decreased by 481.1% year-over-year, from $36.81M to -$140.25M.
What is the long-term trend for Dyne Therapeutics, Inc.'s net change in cash?
Over 2 years (2021 to 2025), Dyne Therapeutics, Inc.'s net change in cash has grown at a 114.5% compound annual growth rate (CAGR), from -$99.63M to $458.35M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Dyne Therapeutics, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude